Pfizer Gains Slightly on Xalkori Data - Analyst Blog


Shutterstock photo

Pfizer Inc. 's ( PFE ) shares inched up 1.05% after it announced positive data from a phase III study evaluating oncology drug, Xalkori, in treatment naive ALK-positive advanced non-small cell lung cancer (NSCLC) patients.

The phase III, PROFILE 1014 study compared the use of Xalkori versus standard platinum-based chemotherapy regimens in patients with advanced NSCLC. The study met its primary endpoint with Xalkori significantly prolonging progression-free survival (PFS) as compared to standard platinum-based chemotherapy regimens.

Results from the PROFILE 1014 study are in line with the positive data from a phase III study (PROFILE 1007) announced in Jun 2012. PROFILE 1007 showed a significant improvement in PFS in previously treated patients with advanced ALK-positive NSCLC compared to Eli Lilly and Company 's ( LLY ) Alimta (pemetrexed) or Sanofi 's ( SNY ) Taxotere (docetaxel).

We remind investors that the U.S. Food and Drug Administration (FDA) had initially granted accelerated approval to Xalkori in Aug 2011. In Nov 2013, the FDA granted regular approval to Xalkori for the treatment of patients with metastatic ALK-positive NSCLC as detected by an FDA-approved test. Xalkori sales were $282 million in 2013, up 129% y/y.

The encouraging data from the phase III, PROFILE 1014 study on Xalkori is a positive for Pfizer. We believe this data will augment Pfizer's label expansion efforts related to Xalkori. Approval for the treatment-naive NSCLC patient population will significantly boost the product's commercial potential.

Pfizer carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Gilead Sciences Inc. ( GILD ). The stock carries a Zacks Rank #1 (Strong Buy).

GILEAD SCIENCES (GILD): Free Stock Analysis Report

LILLY ELI & CO (LLY): Free Stock Analysis Report

PFIZER INC (PFE): Free Stock Analysis Report

SANOFI-AVENTIS (SNY): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Business , Stocks
More Headlines for: PFS , GILD , LLY , PFE , SNY

More from


Equity Research
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by